Investor News Archive

• CryoCath Appoints Vice President, Europe
  7/2/2008
• CryoCath Introduces Arctic Front in Italy, Belgium and Spain
  6/27/2008
• CryoCath Closes Exercise of Over-Allotment Option
  6/6/2008
• CryoCath Announces Exercise of Over-Allotment Option
  6/5/2008
• CryoCath Introduces Arctic Front in Hong Kong
  6/4/2008
• CryoCath Presents at Prestigious Heart Rhythm Society Meeting
  5/20/2008
• CryoCath Announces Fiscal 2008 Second Quarter Results
  5/12/2008
• CryoCath Completes $17.4 Million Bought Deal of Common Shares
  5/7/2008
• CryoCath to Hold Second Quarter 2008 Conference Call and Webcast
  4/30/2008
• CryoCath achieves key milestone of 270 consented patients for STOP AF IDE Trial for its Arctic Front Atrial Fibrillation therapy system
  4/29/2008
• CryoCath Enters into Agreement for a $17.4 Million Bought Deal of Common Shares
  4/17/2008
• CryoCath Reports Data Presented at the 74th Annual Meeting of the German Cardiac Society
  4/3/2008
• CryoCath Introduces Arctic Front in Australia
  3/26/2008
• CryoCath Appoints New Chief Financial Officer
  2/26/2008
• CryoCath Technologies Notice of Annual Meeting
  2/20/2008
• CryoCath Announces Fiscal 2008 First Quarter Results
  2/14/2008
• CryoCath Provides Update on Patent Infringement Lawsuit
  2/14/2008
• CryoCath to Hold First Quarter 2008 Conference Call and Webcast
  2/7/2008
• CryoCath intends to contest patent infringement claim by CryoCor, Inc.
  1/17/2008
• CryoCath Announces 2007 Fourth Quarter and Fiscal Year End Financial Results
  12/17/2007
• CryoCath to present at the 2007 RBC Healthcare Conference
  12/6/2007
• CryoCath to present at Piper Jaffray and BMO Healthcare Conferences
  11/27/2007
• CryoCath to Present at Canaccord Adams Cardiovascular Conference
  11/9/2007
• CryoCath to Present at CIBC Healthcare Conference
  10/30/2007
• CryoCath Reports Positive 12-Month Follow up Data from U.S. AFIB Trial
  10/25/2007
• CryoCath Files Patent Infringement Lawsuit
  10/16/2007
• CryoCath Announces Addition to Board of Directors
  8/30/2007
• CryoCath Announces Fiscal 2007 Third Quarter Results
  8/9/2007
• CryoCath Completes Sale to ATS Medical
  6/28/2007
• CryoCath Reports Positive Data at European Society of Cardiology Conference
  6/28/2007
• CryoCath to Sell Surgical Portfolio to ATS Medical in US$22 Million Transaction
  6/19/2007
• CryoCath to present at Leerink Swann - Rhythm Revival: Atrial Fibrillation Roundtable Conference
  6/5/2007
• CryoCath Announces Fiscal 2007 Second Quarter Results
  5/15/2007
• CryoCath Featured Prominently at 2007 Annual Scientific Sessions of the Heart Rhythm Society
  5/8/2007
• CryoCath reports positive data at German Cardiac Society conference
  4/18/2007
• CryoCath receives FDA approval to expand STOP AF trial to full cohort of patients
  3/28/2007
• CryoCath Reports Positive 6-Month Follow up Data from U.S. AFIB Trial
  3/8/2007
• CryoCath announces fiscal 2007 first quarter financial results
  2/13/2007
• CryoCath Announces New President and CEO
  1/29/2007
• CryoCath treats first patients with new SurgiFrost XL
  1/4/2007
• CryoCath announces 2006 fourth quarter and fiscal year end financial results
  12/21/2006
• CryoCath hires chief financial officer
  12/15/2006
• CryoCath provides twelve month update on pivotal AF study
  12/12/2006
• CryoCath to present at 2006 RBC Capital Markets Health Care Conference
  12/7/2006
• CryoCath receives FDA approval to expand AF trial
  11/28/2006
• CryoCath named to Deloitte’s Technology Fast 500
  11/14/2006
• CryoCath enrolls first patient in U.S. AF trial
  10/19/2006
• CRYOCATH TO PRESENT AT 2006 UBS GLOBAL LIFE SCIENCES CONFERENCE
  9/26/2006
• CRYOCATH RECEIVES FDA APPROVAL TO START AF TRIAL
  9/5/2006
• CRYOCATH ANNOUNCES FISCAL 2006 THIRD QUARTER RESULTS
  8/14/2006
• CRYOCATH ANNOUNCES MANAGEMENT CHANGE
  7/20/2006
• CRYOCATH REPORTS POSITIVE AF DATA AT MAJOR EUROPEAN CONFERENCE
  6/19/2006
• CRYOCATH PROMINENT AT LEADING SCIENTIFIC CONFERENCE
  5/23/2006
• CRYOCATH ANNOUNCES FISCAL 2006 SECOND QUARTER RESULTS
  5/10/2006
• CRYOCATH REPORTS POSITIVE AF DATA AT EUROPEAN CARDIAC CONFERENCE
  4/24/2006
• CRYOCATH PROVIDES UPDATE ON PIVOTAL AF STUDY
  4/3/2006
• CryoCath Announces Fiscal 2006 First Quarter Results
  2/14/2006
• CRYOCATH ANNOUNCES MANAGEMENT CHANGES
  1/20/2006
• CRYOCATH REPORTS POSITIVE DATA AT ATRIAL FIBRILLATION CONFERENCE
  1/16/2006
• CryoCath Announces 2005 Fourth Quarter and Fiscal Year End Financial Results
  12/5/2005
• CRYOCATH ANNOUNCES THE EXTENSION OF THE TERM OF THE OPTION GRANTED TO INVESTISSEMENT QUÉBEC
  11/29/2005
• CryoCath to Present at CIBC World Markets 16th Annual Healthcare Conference
  11/7/2005
• CryoCath Reports Positive 12-month Data for Arctic Front™
  9/6/2005
• CryoCath Announces Fiscal 2005 Third Quarter Results
  8/11/2005
• CryoCath Launches FrostByte™ Globally
  7/20/2005
• CryoCath Receives European Approval for Arctic Front™ System
  7/18/2005
• CryoCath’s U.S. Trial for Atrial Fibrillation Underway
  6/15/2005
• CryoCath Announces Fiscal 2005 Second Quarter Results
  5/12/2005
• CryoCath Receives FDA Approval to Initiate Arctic Front IDE for the Treatment of Atrial Fibrillation
  3/29/2005
• CryoCath Announces Fiscal 2005 First Quarter Results
  2/14/2005
• CryoCath Reports Strong Chronic AF Results
  1/17/2005
• CryoCath announces exercise of over-allotment option
  1/13/2005
• CryoCath Closes $25,000,300 Bought Deal of Common Shares
  12/14/2004
• CryoCath Receives Regulatory Approval to Market Freezor® and Arctic Circler® in China
  11/29/2004
• CryoCath Enters into Agreement for a $25 Million Bought Deal of Common Shares
  11/23/2004
• CryoCath Announces Record 2004 Fourth Quarter and Fiscal Year End Financial Results
  11/11/2004
• CryoCath’s Freezor MAX Obtains FDA Approval in the U.S.
  11/10/2004
• CryoCath & ATS Medical Enter Exclusive Global Partnership
  11/9/2004
• CryoCath Provides AF Program Update
  10/28/2004
• CryoCath Announces 2004 Third Quarter Financial Results
  8/12/2004
• CryoCath Completes Enrollment in First Stage of Atrial Fibrillation Study
  5/27/2004
• CryoCath Announces 2004 Second Quarter Financial Results
  5/12/2004
• CryoCath Announces Exciting Start in Atrial Fibrillation Study With Arctic Circler™ Balloon
  5/10/2004
• CryoCath's FrostByte Receives FDA Clearance, Company Poised to Launch
  5/5/2004
• CryoCath Announces 2004 First Quarter Financial Results
  2/26/2004
• CryoCath's SurgiFrost® Achieves over 90% Success Rates in Treating Atrial Fibrillation
  1/27/2004
• CryoCath Announces 2003 Fourth Quarter and Year-end Financial Results
  12/18/2003
• CryoCath Initiates Patient Enrolment in Atrial Fibrillation Study
  11/17/2003
• CryoCath's Arctic Circler Highlighted at AHA™
  11/13/2003
• CryoCath’s Freezor^® MAX And Freezor^® Xtra Successes in Treating Atrial Flutter Reported at International Conference
  10/14/2003
• CryoCath Closes $25 Million Bought Deal of Common Shares
  10/10/2003
• CryoCath Finalizes Biolevier Loan Agreement with Investissement Quebec
  9/29/2003
• CryoCath Enters into Agreement for a $25 Million Bought Deal of Common Shares
  9/22/2003
• CryoCath's Progress Reported at Analyst Forum
  9/11/2003
• CryoCath Receives FDA Approval To Start Atrial Fibrillation Study
  9/10/2003
• CryoCath Announces Third Quarter 2003 Financial Results
  8/28/2003
• CryoCath Takes Voluntary Field Action to Replace Select Catheter Lots
  8/19/2003
• CryoCath Receives European Approval for CryoVasc™
  7/8/2003
• CryoCath Announces Second Quarter 2003 Financial Results
  5/29/2003
• CryoCath's Freezor® MAX Successfully Treats First Atrial Flutter Cases
  5/22/2003
• CryoCath Gains Key U.S. Patent to Promote Angiogenesis
  5/13/2003
• CryoCath Receives European Approval for Freezor® MAX
  5/12/2003
• CryoCath Receives FDA 510(k) Clearance for Freezor® Xtra
  5/8/2003
• CryoCath Reports First Commercial Use of Freezor® System in U.S.
  5/5/2003
• CryoCath Updates Arctic Circler^TM Progress
  4/28/2003
• CryoCath Receives FDA Approval For Freezor®
  4/22/2003
• CryoCath Fortifies Position in Strategic Surgical Ablation Market
  4/15/2003
• CryoCath’s Freezor® Catheter Recommended For Approval By FDA Expert Panel
  3/7/2003
• CryoCath Announces Record First Quarter 2003 Financial Results
  2/26/2003
• CryoCath Appoints New Chairman
  1/30/2003
• CryoCath Announces Fourth Quarter 2002 and Year End Financial Results
  1/24/2003
• CryoCath Receives Positive FDA Inspection
  1/22/2003
• CryoCath Appoints Robert Mattioli, Vice President North American Sales & Global EP Marketing
  1/7/2003
• CryoCath’s Freezor™ PMA Application Advances
  12/17/2002
• CryoCath Reports New Clinical Application for Freezor™
  12/12/2002
• CryoCath Appoints Gerard Mahoudeau, Director, European Business
  10/28/2002
• CryoCath Submits Final Module to FDA for U.S. Approval of the Freezor™ Cryoablation System
  10/24/2002
• Interim Results of the “ICE” Cryotherapy Restenosis Trial Reported at TCT
  9/30/2002
• CryoCath Appoints Japan Lifeline as Distributor in Japan
  9/25/2002
• CryoCath Announces European Regulatory Approval for Arctic Circler™
  9/17/2002
• CryoCath Closes Bought Deal Financing
  9/10/2002
• CryoCath Files Final Prospectus For $18 Million Bought Deal of Units
  8/30/2002
• CryoCath Announces Third Quarter Financial Results
  8/29/2002
• CryoCath Files Preliminary Prospectus For $18 Million Bought Deal of Units
  8/26/2002
• CryoCath Enters Into Agreement For A $18 Million Bought Deal of Units
  8/21/2002
• CryoCath Announces First Commercial Use of SurgiFrost™ In the USA
  7/11/2002
• CryoCath Receives FDA Acceptance for First Module of PMA Application for Freezor™
  6/20/2002
• CryoCath Launches Surgifrost™ Surgical Cryoablation System in the United States
  6/12/2002
• CryoCath Announces Second Quarter Financial Results
  5/30/2002
• CryoCath Announces Successful Pediatric Use of Freezor™
  4/24/2002
• CryoCath Completes Enrollment in “FROSTY” Pivotal IDE Study For Freezor™
  4/17/2002
• CryoCath Announces Successful First Use of SurgiFrost™
  4/11/2002
• CryoCath Reports Final Results of Ischemia Study
  3/18/2002
• CryoCath Technologies File Final Prospectus Qualifying Distribution Of Shares Issuable Upon Exercise Of Special Warrants
  2/27/2002
• CryoCath Achieves Strong Sales Growth in First Quarter
  2/26/2002
• CryoCath Receives European Approval For Freezor™ Xtra
  2/26/2002
• CryoCath Makes Two Strategic Appointments
  2/7/2002
• CryoCath Joins TSE 300 Index
  1/24/2002
• CryoCath Receives Approval to Sell Freezor™ Catheter System in Canada
  1/22/2002
• CryoCath Gets FDA Approval for Modular Filing Plan for PMA Application for Freezor™ System
  1/15/2002
• CryoCath Announces Year-End 2001 Financial Results
  1/9/2002
• CryoCath Announces Webcast of 2001 Year-end Results
  1/7/2002
• CryoCath enters into agreement for a $21 million bought deal of special warrants
  12/10/2001
• CryoCath Announces First Human Clinical Use of Arctic Circler™ to Treat Atrial Fibrillation
  12/6/2001
• Cryoablation’s Superior Safety Profiled at Major Cardiology Conference
  11/14/2001
• CryoCath Announces Strong European Sales Growth in Fourth Quarter
  10/18/2001
• Endocare and CryoCath form strategic alliance to penetrate surgical cardiac arrhythmia market
  9/25/2001
• Erratum
  8/31/2001
• CryoCath Announces Third Quarter 2001 Financial Results
  8/28/2001
• CryoCath’s European launch gathering momentum
  6/21/2001
• CryoCath gains key U.S. method patent to treat restenosis
  6/6/2001
• CryoCath Announces Second Quarter 2001 Financial Results
  5/29/2001
• Live Telecast of CryoCath’s Freezor™ Cardiac CryoAblation Procedure Receives Enthusiastic Reception at Prestigious International Conference
  5/7/2001
• CryoCath’s Freezor™ Cardiac CryoAblation System Approved for Sale Across Europe.
  3/29/2001
• CryoCath takes important step towards U.S. approval with start of pivotal clinical trial
  3/20/2001
• CryoCath Announces First Quarter 2001 Financial Results
  2/27/2001
• CryoCath successfully initiates clinical feasibility study to treat restenosis with cryotherapy
  2/22/2001
• CryoCath Announces Year-End 2000 Financial Results
  2/16/2001
• CryoCath Announces the World’s First Catheter-based Cryoablation Procedure for the Treatment of Atrial Fibrillation (AF)
  12/11/2000
• CryoCath Successfully Initiates Clinical Studies with its New 7F Freezor™ Catheter Cryotherapy System
  11/30/2000
• CryoCath Technologies Announces Change in Fiscal Year
  11/28/2000
• CryoCath Initiates Enrollment in its Pilot-study of Low-temperature Angiogenic Revascularization (POLAR) Study
  11/16/2000
• CryoCath Technologies Raises $40 Million in Initial Public Offering of Shares Listed for Trading on TSE
  10/31/2000
• CryoCath Technologies Announces Receipt of CE Mark
  6/15/2000
• CryoCath Closes Largest Placement Ever For a Private Canadian Medical Devices Company
  6/7/2000
• CryoCath Technologies Inc. Announces the Successful Start of Clinical Trials Using the Frostline™ Linear Cryoablation System
  6/1/2000
• CryoCath Technologies Appoints Katherine Crewe, P.Eng. as Vice-President, Operations
  5/18/2000
• CryoCath Technologies Receives ISO 9001 Certification
  5/11/2000
• CryoCath Technologies Appoints David A. Smith as Vice President, Marketing and Sales
  5/8/2000
• CryoCath Technologies Appoints Willard W. (Bill) Hennemann, PhD as Vice-President, Research and Development
  1/24/2000
• CryoCath Technologies Treats First Three Patients of Multi-center Investigational Device Exemption in the USA
  1/12/2000
• CryoCath Technologies Expands Study in Catheter Cryoablation of Cardiac Arrhythmia Following FDA Provisional Approval
  11/18/1999
• CryoCath Technologies Strengthens its Dominant Intellectual Property Position in Catheter-based Cryoablation
  9/7/1999
• CryoCath Technologies Announces New Cardiovascular Catheter Systems Development and Pilot Production Facility in Kirkland, Québec
  5/21/1999
• CryoCath Successfully Expands its Human Clinical Studies for Cardiac Arrhythmia
  5/13/1999
• CryoCath Completes a Third-Round Private Placement for CDN$10 Million
  4/7/1999
• CryoCath Technologies’ Pioneering Efforts in Restenosis Receives Significant Support from the National Research Council of Canada
  1/21/1999
• CryoCath Technologies Inc. Successfully Treats First Cardiac Arrhythmia Patient
  9/21/1998
• CryoCath names Donald J. Larnard, Ph.D., Chief Technology Officer
  2/9/1998
• CryoCath Technologies Raises $14.6 Million (CDN) in Second Round of Financing
  1/30/1998